Results 21 to 30 of about 16,167 (200)
American Journal of Ophthalmology Case Reports, 2023 Purpose: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use.
Mohamad El Wardani, Marc D. de Smet
doaj +1 more source
Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Frontiers in Endocrinology, 2021 ObjectiveTo investigate how often target renin is pursued and achieved in patients with primary aldosteronism (PA) and other low renin hypertension (LRH) treated with mineralocorticoid receptor antagonists (MRAs), as reversal of renin suppression was ...
Yuta Tezuka, Yuta Tezuka, Adina F. Turcu
doaj +1 more source
Mineralocorticoid receptor antagonists for heart failure [PDF]
Expert Opinion on Pharmacotherapy, 2011 Although mineralocorticoid receptor (MR) antagonists are indicated in systolic heart failure, they are underprescribed in patients with appropriate indications for their prescription and often used in those in whom the evidence for probable benefit is scant.
openaire +4 more sources
Consilium Medicum, 2022 Mineralocorticoid receptor antagonists (MRAs) are part of basic medical therapy for heart failure. The clinical efficacy of MRAs has been proven by randomized clinical trials. To review comparative efficacy and tolerability data between the two main MRAs,
Natalia V. Safronova +2 more
doaj +1 more source
Frontiers in Physiology, 2022 Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production.
Roberto Palacios-Ramirez +10 more
doaj +1 more source
Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease [PDF]
International Journal of Molecular Sciences, 2021 Mineralocorticoid receptor antagonists (MRA) are drugs with a potentially broad spectrum of action. They have been reported to have healing effects in many diseases, such as chronic heart failure, hypertension, or nephrotic syndrome. Numerous studies suggest that mineralocorticoid receptor activation is pathogenic and a progression factor of chronic ...
Wiktoria Baran +6 more
openaire +2 more sources
Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome [PDF]
Current Hypertension Reports, 2010 Key components of the metabolic syndrome (MetS), ie, obesity and insulin resistance, are associated with increased aldosterone production and mineralocorticoid receptor (MR) activation. Both MetS and hyperaldosteronism are proinflammatory and pro-oxidative states associated with cardiovascular disease.
Amir, Tirosh +2 more
openaire +2 more sources
Heart failure: the role for mineralocorticoid receptor antagonists
Swiss Medical Weekly, 2014 Mineralocorticoid receptor antagonists (MRA’s) have been shown to be effective in patients with HFREF while their role in patients with HFPEF remains controversial. Despite a class one indication in both the ESC and AHA/ACC heart failure guidelines
Bertram Pitt
doaj +1 more source
Endocrinology, Diabetes & Metabolism Case Reports, 2021 Primary aldosteronism is one of the most common (affecting up to 10%) yet treatable causes of hypertension in our community, notable due to an associated elevated risk of atrial fibrillation, stroke and myocardial infarction compared to essential ...
Lachlan M Angus, Jun Yang, Ada S Cheung
doaj +1 more source
Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
Frontiers in Pharmacology, 2022 Diabetic kidney disease (DKD) is one of the major causes of end-stage renal disease (ESRD). To evaluate the efficacy and safety of different types of mineralocorticoid receptor antagonists (MRAs) in diabetic kidney disease patients, we conducted this ...
Yichuan Wu +13 more
doaj +1 more source